Editing Novo Nordisk A/S (section)

== Projects ==
Novo Nordisk has a number of projects in development in the areas of diabetes, obesity, rare diseases, and growth hormone. Some of the most notable projects include:

'''Currently in development'''

<u>Semaglutide injection pen</u> 

This is a new formulation of Novo Nordisk's flagship diabetes drug, Ozempic. The injection pen is designed to be easier to use and more convenient for patients.<ref>https://www.novomedlink.com/diabetes/patient-support/product-education/library/ozempic-pen-instructions-for-use.html</ref>

<u>TT-003</u>

This is a new drug for the treatment of obesity. TT-003 is a combination of two drugs, semaglutide and exenatide. TT-003 is currently in Phase 3 clinical trials.<ref>https://www.frontiersin.org/articles/10.3389/fendo.2020.00568/full</ref>

<u>NN9031</u> 

This is a new drug for the treatment of type 1 diabetes. NN9031 is a long-acting insulin that is designed to be more effective and less likely to cause hypoglycaemia than current insulin therapies. NN9031 is currently in Phase 2 clinical trials.

<u>NSG005</u> 

This is a new drug for the treatment of growth hormone deficiency. NSG005 is a long-acting growth hormone that is designed to be more effective and less likely to cause side effects than current growth hormone therapies. NSG005 is currently in Phase 3 clinical trials.<ref>https://oa.mg/author/r-krishna-murthy-karuturi-A2089560729</ref>

In addition to these projects, Novo Nordisk is also developing a number of other drugs and technologies for the treatment of diabetes, obesity, rare diseases, and growth hormone. The company is committed to continuous innovation, and is always looking for new ways to improve the lives of patients.


'''Most successful products'''

* Ozempic: This is a once-weekly injection for the treatment of type 2 diabetes. Ozempic is a GLP-1 agonist, a type of drug that helps to control blood sugar levels by mimicking the effects of the hormone glucagon-like peptide-1. Ozempic was approved by the FDA in 2017, and has since become one of Novo Nordisk's top-selling drugs.<ref>https://diatribe.org/fda-approves-ozempic-powerful-once-weekly-type-2-diabetes-medication</ref>

[[File:Ozempic.png|center|thumb|412x412px]]

* Rybelsus: This is a once-daily pill for the treatment of type 2 diabetes. Rybelsus is also a GLP-1 agonist, and was approved by the FDA in 2019. Rybelsus is the first GLP-1 agonist that can be taken once daily, and has been shown to be effective in controlling blood sugar levels.<ref>https://www.europeanpharmaceuticalreview.com/news/100641/first-oral-glp-1-treatment-type-2-diabetes-approved/</ref>

[[File:Rybelsus.png|center|thumb|315x315px]]

* Wegovy: This is a once-weekly injection for the treatment of obesity. Wegovy is also a GLP-1 agonist, and was approved by the FDA in 2021. Wegovy is the first GLP-1 agonist that has been shown to be effective in helping people lose weight, and has been shown to be safe and well-tolerated.<ref>https://www.theguardian.com/society/2023/feb/13/weight-loss-jabs-to-be-sold-via-high-street-chemists</ref>
[[File:Wegovy picture.webp|center|thumb|489x489px]]
Novo Nordisk is a leading global pharmaceutical company with a strong track record of innovation. The company is committed to finding new and innovative ways to treat diabetes, obesity, rare diseases, and growth hormone. Novo Nordisk is also committed to making its products more affordable and accessible to patients around the world.